I respect your opinion but I'm still a little confused why you...

I respect your opinion but I'm still a little confused why you fund it inappropriate to compare market caps with peers?

Perhaps some of the most important questions to any investor is, are we overvalued, are we undervalued, what is our room for growth?

It's absolutely not disrespecting any of our peers, it's simply Steven doing a good job in highlighting the fact we are undervalued compared to many of our peers and also what we can potentially look forward to with some of our peers at certain clinical milestones.

Even in the instance of Folotyn, Steven is critically identifying for investors the benchmark for potentially moving to a registrational trial & FDA approval. He isn't trying to bring the efficacy of Folotyn to attention as a put down, more so just trying to express that PTX-100 is targeting a very unmet need and that the prospects of our product moving to market will not be dictated by extremely high efficacy. Clearly we would love to see 100% efficacy but Steven is just highlighting that even 20-30% could be enough for the FDA to give approval to something with a complete safety profile given the unmet needs of PTCL & TCL patients.

Folotyn may not even lose huge market share? It's important to remember that many patients will trial multiple therapies at different stages of their illness and possibly in combination with other therapies so it's not necessarily always the Highlander 'There can only be one' adversarial scenario.

It's critical for any company in my opinion to both compare themselves to peers, but equally to educate investors when it comes to identifying value. There's no rewards for modesty in business, we are looking genuinely undervalued and I personally appreciate Steven's proactive marketing approach.

Again, respect your opinions and this is just healthy conversation of differing perspectives. Enjoy your Sunday mate and hopefully tomorrow is another great day for us.

Cheers.